ArticleMedicine2026
Estimated glucose disposal rate and markers of liver injury: A population-based study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To estimate the glucose disposal rate (eGDR) as a newly validated surrogate marker of insulin resistance, this study examines its association with liver dysfunction, a relationship seldom explored. Accordingly, this research aims to investigate potential correlations between eGDR and markers of liver injury. This analysis utilized data from the National Health and Nutrition Examination Survey spanning 2005 to 2018. Multiple linear regression models were employed to assess the association between eGDR and markers of liver injury. Secondary analyses included subgroup evaluations and restricted cubic spline modeling. In the fully adjusted model, eGDR demonstrated a significant negative association with alanine aminotransferase (ALT) (β = -2.25, 95% CI: -2.66 to -1.84, P < .0001), aspartate aminotransferase (AST) (β = -0.66, 95% CI: -0.90 to -0.42, P < .0001), alkaline phosphatase (ALP) (β = -2.55, 95% CI: -2.96 to -2.13, P < .0001), and gamma-glutamyl transferase (GGT) (β = -2.85, 95% CI: -3.33 to -2.37, P < .0001). A nonlinear negative correlation was identified between eGDR and markers of liver injury (P for nonlinearity < .05). In each subgroup, eGDR was not correlated with ALT in non-Hispanic Black, hypertensive patients, and diabetes mellitus (DM) patients, but showed a significant negative correlation in all other subgroups (all P < .05). Interaction tests revealed significant differences in the correlation between eGDR and ALT across age, ethnicity, body mass index (BMI), cancer presence, and hypertension strata (P for interaction < .05). Similarly, eGDR's correlation with AST varied significantly across strata of age, ethnicity and hypertension (P for interaction < .05). Furthermore, the correlation between eGDR and ALP) showed significant variation across age, sex, BMI, and hypertension strata (P for interaction < .05). Finally, eGDR's correlation with GGT varied significantly across age, ethnicity, BMI, hypertension, and DM strata (P for interaction < .05). This cross-sectional study identified a negative association between eGDR and markers of liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.